• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Omnicell Inc.

    7/7/26 4:02:41 PM ET
    $OMCL
    Computer Manufacturing
    Technology
    Get the next $OMCL alert in real time by email
    S-8 1 forms-82026x07.htm S-8 Document


    As filed with the Securities and Exchange Commission on July 7, 2026
    Registration No. 333-
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    ____________________________________________________________________________
    FORM S-8
    REGISTRATION STATEMENT UNDER
    THE SECURITIES ACT OF 1933
    OMNICELL, INC.
    (Exact name of registrant as specified in its charter)
    Delaware
    (State or other jurisdiction of incorporation or organization)
    94-3166458
    (I.R.S. Employer Identification No.)
    4220 North Freeway
    Fort Worth, TX 76137
    (Address of principal executive offices, including zip code)
    Omnicell, Inc. 2009 Equity Incentive Plan, as amended
    (Full title of the plans)
    Randall A. Lipps
    Chief Executive Officer and Chairman of the Board
    4220 North Freeway
    Fort Worth, TX 76137
    (877) 415-9990
    (Name, address, including zip code, and telephone number, including area code, of agent for service)
    ____________________________________________________________________________
    Copies to:
    Jessica S. Lochmann
    Foley & Lardner LLP
    777 East Wisconsin Avenue
    Milwaukee, Wisconsin 53202-5304
    (414) 271-2400
    ____________________________________________________________________________
        Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:
    Large accelerated filer ☒
    Accelerated filer ☐
    Non-accelerated filer ☐

    Smaller reporting company ☐
    Emerging growth company ☐
        If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐




    EXPLANATORY NOTE
    Omnicell, Inc. (the “Registrant”) is filing this Registration Statement on Form S-8 for the purpose of registering 1,600,000 shares of the Registrant’s common stock (the “Common Stock”) issuable to eligible persons under the Omnicell, Inc. 2009 Equity Incentive Plan, as amended (the “2009 Plan”), which Common Stock is in addition to the shares of Common Stock previously registered on the Registration Statements on Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on May 29, 2009 (File No. 333-159562), August 8, 2011 (File No. 333-176146), August 30, 2013 (File No. 333-190930), July 2, 2015 (File No. 333-205465), May 24, 2018 (File No. 333-225179), May 22, 2019 (File No. 333-231669), June 10, 2021 (File No. 333-256979), June 22, 2022 (File No. 333-265767), May 26, 2023 (File No. 333-272242), June 21, 2024 (File No. 333-280384), and June 18, 2025 (File No. 333-288140) (collectively, the “Prior Registration Statements”).
    This Registration Statement relates to securities of the same class as that to which the Prior Registration Statements relate, and is submitted in accordance with General Instruction E of Form S-8 regarding Registration of Additional Securities. Pursuant to General Instruction E of Form S-8, the contents of the Prior Registration Statements, to the extent relating to the registration of Common Stock issuable under the 2009 Plan, are incorporated by reference into this Registration Statement and made part of this Registration Statement, except as amended hereby.
    PART I
    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
    The document or documents containing the information specified in Part I of this Registration Statement are not required to be filed with the Commission as part of this Registration Statement on Form S-8 and will be sent or given to the participants in the 2009 Plan as specified by Rule 428(b)(1) under the Securities Act of 1933, as amended.
    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
    ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE.
    The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:
    1.    The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Commission on February 26, 2026 (the “2025 Form 10-K”);
    2.    The information specifically incorporated by reference into the 2025 Form 10-K from the Registrant’s Definitive Proxy Statement on Schedule 14A, filed with the Commission on April 13, 2026;
    3.    The Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026, filed with the Commission on May 6, 2026;
    4.    The Registrant’s Current Reports on Form 8-K, filed with the Commission on May 26, 2026, and July 1, 2026;
    5.    All other reports filed by the Registrant pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), since the end of the fiscal year covered by the 2025 Form 10-K;
    6.    The description of the Registrant’s Common Stock contained in the Registrant’s registration statement on Form 8-A filed with the Commission on August 3, 2001, as updated by the Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Exchange Act filed as Exhibit 4.7 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, including any amendments or reports filed for the purpose of updating such description; and
    7.    All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or
    2


    superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
    3


    ITEM 8. EXHIBITS
    Incorporated By Reference
    Exhibit Number
    Exhibit Description
    Form
    File No.
    Exhibit
    Filing Date
    4.1
    Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Omnicell, Inc.
    8-K
    000-33043
    3.1
    5/26/2026
    4.2
    Certificate of Designation of Series A Junior Participating Preferred Stock
    10-K
    000-33043
    3.2
    3/28/2003
    4.3
    Fourth Amended and Restated Bylaws of Omnicell, Inc.
    8-K
    000-33043
    3.1
    10/6/2025
    4.4
    Form of Common Stock Certificate
    S-1/A
    333-57024
    4.1
    7/24/2001
    5.1+
    Opinion of Foley & Lardner LLP as to the legality of securities being registered
    23.1+
    Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm
    23.2+
    Consent of Foley & Lardner LLP (included in Exhibit 5.1 to this Registration Statement)
    24.1+
    Power of Attorney (included on the signature page of this Registration Statement)
    99.1*+
    Omnicell, Inc. 2009 Equity Incentive Plan, as amended
    107.1+
    Calculation of Filing Fee Table
    _________________________________________________
    *    Indicates a management contract, compensation plan, or arrangement.
    +    Filed herewith.
    4


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Portola Valley, State of California, on this 7th day of July, 2026.

    OMNICELL, INC.
    By:/s/ H. Baird Radford, III
    Baird Radford
    Executive Vice President and Chief Financial Officer
    (Principal Financial Officer)
    5


    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Randall A. Lipps and H. Baird Radford, III, and each or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission (the “Commission”), and generally to do all such things in their names and behalf in their capacities as officers and directors to enable the Registrant to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
    Signature
    Title
    Date
    /s/ RANDALL A. LIPPS
    Chief Executive Officer and Chairman of the Board
    (Principal Executive Officer)
    July 7, 2026
    Randall A. Lipps
    /s/ H. BAIRD RADFORD, III
    Executive Vice President and Chief Financial Officer
    (Principal Financial Officer)
    July 7, 2026
    Baird Radford
    /s/ BRIAN H. NUTT
    Vice President, Chief Accounting Officer and Corporate Controller
    (Principal Accounting Officer)
    July 7, 2026
    Brian H. Nutt
    /s/ JOANNE B. BAUER
    Director
    July 7, 2026
    Joanne B. Bauer
    /s/ EDWARD P. BOUSA
    Director
    July 7, 2026
    Edward P. Bousa
    /s/ MARY A. GARRETT
    Director
    July 7, 2026
    Mary A. Garrett
    /s/ KAUSHIK GHOSHALDirectorJuly 7, 2026
    Kaushik Ghoshal
    /s/ MARK W. PARRISH
    Director
    July 7, 2026
    Mark W. Parrish
    /s/ BRUCE E. SCOTT
    Director
    July 7, 2026
    Bruce E. Scott
    /s/ ROBIN G. SEIM
    Director
    July 7, 2026
    Robin G. Seim
    /s/ EILEEN J. VOYNICK
    Director
    July 7, 2026
    Eileen J. Voynick

    6
    Get the next $OMCL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OMCL

    DatePrice TargetRatingAnalyst
    2/4/2026$70.00Neutral → Buy
    BofA Securities
    1/8/2026$60.00Sector Weight → Overweight
    KeyBanc Capital Markets
    5/14/2025$35.00Equal Weight → Overweight
    Wells Fargo
    10/31/2024$44.00 → $57.00Buy → Neutral
    BofA Securities
    8/2/2024$26.00 → $39.00Underweight → Equal Weight
    Barclays
    1/3/2024$33.00Underweight
    Barclays
    11/3/2023$39.00 → $28.00Underweight → Equal Weight
    Wells Fargo
    11/3/2023Buy → Neutral
    BTIG Research
    More analyst ratings

    $OMCL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHAIRMAN, CEO Lipps Randall A sold $470,000 worth of shares (10,000 units at $47.00) as part of a pre-agreed trading plan (SEC Form 4)

    4 - OMNICELL, INC. (0000926326) (Issuer)

    7/17/26 4:05:07 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    President & COO Njoku Nnamdi was granted 12,309 shares, increasing direct ownership by 8% to 167,094 units (SEC Form 4)

    4 - OMNICELL, INC. (0000926326) (Issuer)

    7/6/26 4:05:10 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    Director Bousa Edward Peter was granted 4,603 shares, increasing direct ownership by 26% to 22,589 units (SEC Form 4)

    4 - OMNICELL, INC. (0000926326) (Issuer)

    6/3/26 4:05:19 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    $OMCL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHAIRMAN, PRESIDENT AND CEO Lipps Randall A bought $349,874 worth of shares (10,561 units at $33.13) and was granted 79,494 shares, increasing direct ownership by 28% to 413,104 units (SEC Form 4)

    4 - OMNICELL, INC. (0000926326) (Issuer)

    3/18/25 4:13:27 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    $OMCL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $OMCL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Omnicell to Release Second Quarter 2026 Financial Results on July 30, 2026

    Omnicell, Inc. (NASDAQ:OMCL), a leading healthcare technology provider focused on empowering autonomous medication management, will release its financial results for the second quarter 2026, before market open on Thursday, July 30, 2026. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day. All interested parties are invited to listen to the live call and presentation by dialing (833) 461-5787 in the U.S. or (585) 542-9983 in international locations. The Conference ID is 656119963. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell’s website at https://ir.omnicell.com/ev

    7/13/26 4:01:00 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    Nnamdi Njoku Appointed President of Omnicell

    Njoku continues to lead global operations and advance Omnicell's innovation and AI platform strategy; Randall Lipps continues to serve as Chief Executive Officer and Chairman of the Board Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leading healthcare technology provider focused on empowering autonomous medication management, today announced that Nnamdi Njoku has been appointed President of the Company, effective July 1, 2026. Mr. Njoku will retain his role of Chief Operating Officer (COO), while Randall Lipps will continue to serve as Chief Executive Officer and Chairman of the Board, with a continued focus on strategic collaborations and the long-term evolution of Omnic

    7/1/26 8:15:00 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    Omnicell Selects Dan Mandoli to Lead Specialty Pharmacy Services Business

    Seasoned healthcare executive with deep expertise in specialty pharmacy operations named Senior Vice President and General Manager Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leading healthcare technology provider focused on empowering autonomous medication management, today announced that Dan Mandoli, a seasoned healthcare executive with more than 30 years of leadership across pharmacy operations and specialty pharmacy services, has joined the Company as Senior Vice President and General Manager, Specialty Pharmacy Services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608580918/en/Omnicell Welcomes Dan

    6/8/26 8:30:00 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    Omnicell upgraded by BofA Securities with a new price target

    BofA Securities upgraded Omnicell from Neutral to Buy and set a new price target of $70.00

    2/4/26 8:25:37 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    Omnicell upgraded by KeyBanc Capital Markets with a new price target

    KeyBanc Capital Markets upgraded Omnicell from Sector Weight to Overweight and set a new price target of $60.00

    1/8/26 8:12:33 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    Omnicell upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Omnicell from Equal Weight to Overweight and set a new price target of $35.00

    5/14/25 8:50:33 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    $OMCL
    SEC Filings

    View All

    SEC Form S-8 filed by Omnicell Inc.

    S-8 - OMNICELL, INC. (0000926326) (Filer)

    7/7/26 4:02:41 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    Omnicell Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - OMNICELL, INC. (0000926326) (Filer)

    7/1/26 8:27:47 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    SEC Form SD filed by Omnicell Inc.

    SD - OMNICELL, INC. (0000926326) (Filer)

    5/29/26 4:04:15 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    $OMCL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

    SC 13G/A - OMNICELL, INC. (0000926326) (Subject)

    12/11/23 9:36:42 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

    SC 13G/A - OMNICELL, INC. (0000926326) (Subject)

    9/11/23 1:33:44 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

    SC 13G/A - OMNICELL, INC. (0000926326) (Subject)

    2/9/23 11:27:45 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    $OMCL
    Financials

    Live finance-specific insights

    View All

    Omnicell to Release Second Quarter 2026 Financial Results on July 30, 2026

    Omnicell, Inc. (NASDAQ:OMCL), a leading healthcare technology provider focused on empowering autonomous medication management, will release its financial results for the second quarter 2026, before market open on Thursday, July 30, 2026. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day. All interested parties are invited to listen to the live call and presentation by dialing (833) 461-5787 in the U.S. or (585) 542-9983 in international locations. The Conference ID is 656119963. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell’s website at https://ir.omnicell.com/ev

    7/13/26 4:01:00 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    Omnicell Announces First Quarter 2026 Financial Results

    Omnicell delivers strong first quarter 2026 financial results Raises full year 2026 non-GAAP EBITDA and non-GAAP EPS guidance Customer engagement underway for Omnicell Titan XT and OmniSphere Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," or the "Company"), a leading healthcare technology provider focused on empowering autonomous medication management, today reported financial results for the first quarter ended March 31, 2026. First quarter results reflected strong execution across the business, supported by demand for Omnicell's connected device portfolio and solid performance across the Company's core points of care solutions. We believe that performance during the quarte

    4/28/26 6:30:00 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    Omnicell to Release First Quarter 2026 Financial Results on April 28, 2026

    Omnicell, Inc. (NASDAQ:OMCL), a leading healthcare technology provider focused on empowering autonomous medication management, will release its financial results for the first quarter 2026, before market open on Tuesday, April 28, 2026. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day. All interested parties are invited to listen to the live call and presentation by dialing (800) 715-9871 in the U.S. or (646) 307-1963 in international locations. The Conference ID is 9381205. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell's website at https://ir.omnicell.com/event

    4/13/26 5:00:00 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    $OMCL
    Leadership Updates

    Live Leadership Updates

    View All

    Omnicell Welcomes Hospital Pharmacy Leader Rick Couldry as Senior Vice President, Chief Pharmacy and Clinical Officer

    Newly established role strengthens understanding of healthcare clinician needs to help shape the Company's innovation priorities and portfolio decisions Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leading healthcare technology provider focused on empowering autonomous medication management, today announced that Rick Couldry has joined the Company as Senior Vice President, Chief Pharmacy and Clinical Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429498071/en/Omnicell Welcomes Rick Couldry to the Newly-Created Role of SVP, Chief Pharmacy and Clinical Officer In this newly created position, Couldry

    4/29/26 8:00:00 AM ET
    $OMCL
    Computer Manufacturing
    Technology

    Omnicell Appoints Baird Radford as Executive Vice President and Chief Financial Officer

    Seasoned leader brings more than 30 years of experience driving growth for healthcare and technology companies Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced the appointment of Baird Radford as Executive Vice President and Chief Financial Officer of the Company, effective August 26, 2025. Mr. Radford succeeds Nchacha Etta, who will be stepping down from the role, as announced earlier this year. Mr. Etta will remain with the Company in an advisory role through November 2025 to help ensure a smooth transition of responsibilities. This press release features multimedia. View the full release

    8/25/25 4:05:00 PM ET
    $OMCL
    Computer Manufacturing
    Technology

    Omnicell Appoints Nnamdi Njoku as Executive Vice President and Chief Operating Officer

    The Company taps business and operations executive with expertise that spans healthcare and med tech to help scale pharmacy automation and drive multi-year innovation and excellence Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy care delivery model, today announced that Nnamdi Njoku has been appointed Executive Vice President and Chief Operating Officer of the Company, effective October 7, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240925324631/en/Nnamdi Njoku has been appointed Executive Vice President and Chief Operating Officer of Omnicell, effective October 7, 2024

    9/25/24 4:01:00 PM ET
    $OMCL
    Computer Manufacturing
    Technology